Showing 1407 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;…
-
Press release /APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare…
-
Ad hoc release /Novartis to acquire Endocyte to accelerate development of innovative radioligand technology for treating cancer Acquisition would add 177Lu-PSMA-617, a potential first-in-class…
-
Press release /In the FUTURE 1 study, secukinumab showed rapid and significant efficacy in active psoriatic arthritis (PsA) patients, including improvement of skin and joint disease and reduction in progression of…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol…
-
Press release /The agreement includes two clinical stage molecules for schizophrenia and movement disorders and MIJ821, a clinical stage molecule previously licensed exclusively by Novartis for addressing treatment…
-
Story / -
Ad hoc release /Hausse du chiffre d'affaires net de 5% (tcc[1], +7% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 701 millions, (+40% tcc), enregistrant une forte croissance dans toutes ses…
-
Story /Novartis CEO Vas Narasimhan answers questions about COVID-19.